We have enjoyed a very positive experience [that has] prompted us to deploy Genedata Screener globally to harmonize our data analysis workflow internally, and we look forward to the continued expansion of our successful relationship with Genedata.
BASEL, Switzerland (PRWEB)
February 18, 2021
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Evotec, the global drug discovery alliance and development partnership company, has expanded its deployment of Genedata Screener® to its research sites worldwide. This broad adoption of Genedata Screener helps Evotec to drive its research with standardized assay data of the highest quality, and to simplify collaborative workflows on projects across sites and with biopharma customers globally.
Evotec has now adopted Genedata Screener for all assay types, in particular for the analysis of its modern assay portfolio such as automated patch clamp screening, quantitative reverse transcription PCR, and high content screening, and to support its high throughput screening, hit-to-lead, compound profiling and safety testing programs.
Following the global roll-out, Evotec is able to switch from its legacy analysis tools and systems to the harmonized, technologically advanced system provided by Genedata Screener, with its capacity to analyze newer assay types, its centralized cost-effective global deployment, and Genedata’s commitment to continuous development in support of increasing laboratory automation and digitalization. Standardizing on Genedata Screener enables advanced process automation and workflow digitalization, including workflow cost savings for Evotec.
Dirk Ullmann, Ph.D., Global Head of Drug Discovery Services at Evotec commented, “We have been working closely with Genedata scientists who have displayed a deep understanding of our R&D processes and workflows. We have enjoyed a very positive experience with Genedata Screener and seen a significant evolution of the software over that period to continually address our needs and those of our partners in the biopharma industry. These experiences have prompted us to deploy Genedata Screener globally to harmonize our data analysis workflow internally, and we look forward to the continued expansion of our successful relationship with Genedata.”
“We are excited about our long-term collaboration with Evotec and our goal to automate complex R&D workflows, enabling Evotec to accelerate their research programs,” noted Othmar Pfannes, Ph.D., CEO of Genedata. “We are working towards a fully integrated analysis workflow system that produces rapid results that can be summarized and reported at the click of a single button. By rolling out Genedata Screener across their research sites, Evotec validates our joint vision of making biopharma R&D more efficient.”
Genedata presented a poster authored in conjunction with Evotec at the ELRIG Drug Discovery Digital meeting in October 2020, entitled Automating High-Throughput RT-qPCR Analysis for RNA Drug Discovery. The poster provides an overview of the application of Genedata Screener to this modern assay type and is available for download on the Genedata website.
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
About Evotec SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.
Phone: +41 61 511 85 61
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Share article on social media or email: